OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Phesi identified 117,463 patients who participated in disease modifying trials; representing a significant portion of the patient population. The Phesi analysis reveals the decline that occurs in Alzheimer’s patients over a single 12-month period, with the average 72-year-old suffering from Alzheimer’s losing 18% of cognitive function (measured by MMSE) in 12 months.
Read more about the analysis here.